Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Romosozumab Phase 2 in Postmenopausal Osteoporosis
NCT00896532Phase 2Completed
- Sponsor
- Amgen
- Start
- Jun 2009
- Primary completion
- Feb 2011
- Modality
- Monoclonal Antibodies
01
Overview
A Phase 2 trial of romosozumab in postmenopausal osteoporosis, sponsored by Amgen. Started Jun 2009; status: completed.
02
Drugs
romosozumab
03
Conditions
postmenopausal osteoporosis
Beyond the preview
Go deeper on NCT00896532.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00896532.